[go: up one dir, main page]

WO2004099366A3 - Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc - Google Patents

Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc Download PDF

Info

Publication number
WO2004099366A3
WO2004099366A3 PCT/US2003/034010 US0334010W WO2004099366A3 WO 2004099366 A3 WO2004099366 A3 WO 2004099366A3 US 0334010 W US0334010 W US 0334010W WO 2004099366 A3 WO2004099366 A3 WO 2004099366A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna binding
zinc finger
binding domains
context sensitive
finger dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/034010
Other languages
English (en)
Other versions
WO2004099366A2 (fr
Inventor
Keith J Joung
Carl Pabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Institute of Technology
Original Assignee
General Hospital Corp
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Institute of Technology filed Critical General Hospital Corp
Priority to US10/532,258 priority Critical patent/US20070178454A1/en
Priority to AU2003304086A priority patent/AU2003304086A1/en
Publication of WO2004099366A2 publication Critical patent/WO2004099366A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004099366A3 publication Critical patent/WO2004099366A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes destinées à identifier des polypeptides Zf à doigts multiples se liant à une séquence d'intérêt. Les polypeptides Zf identifiés au moyen des méthodes susmentionnées peuvent présenter une affinité et une spécificité pour leurs sites cibles supérieures par rapport à ceux produits au moyen d'autres méthodes.
PCT/US2003/034010 2002-10-21 2003-10-23 Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc Ceased WO2004099366A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/532,258 US20070178454A1 (en) 2002-10-21 2003-10-23 Context sensitive paralell optimization of zinc finger dna binding domains
AU2003304086A AU2003304086A1 (en) 2002-10-23 2003-10-23 Context sensitive parallel optimization of zinc finger dna binding domains

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60/420,485 2002-10-21
US42045802P 2002-10-23 2002-10-23
US46688903P 2003-04-30 2003-04-30
US60/466,889 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004099366A2 WO2004099366A2 (fr) 2004-11-18
WO2004099366A3 true WO2004099366A3 (fr) 2006-07-20

Family

ID=33436673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034010 Ceased WO2004099366A2 (fr) 2002-10-21 2003-10-23 Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc

Country Status (2)

Country Link
AU (1) AU2003304086A1 (fr)
WO (1) WO2004099366A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461896B1 (fr) 2011-07-15 2023-11-29 The General Hospital Corporation Procédés d'assemblage d'effecteurs de type activateur de la transcription
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (fr) 2012-10-12 2021-03-10 The General Hospital Corporation Protéines de fusion effecteur de type activateur de transcription (tale) - déméthylase 1 spécifique de la lysine (lsd1)
AU2014214719B2 (en) 2013-02-07 2020-02-13 The General Hospital Corporation Tale transcriptional activators
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN113563476A (zh) 2013-03-15 2021-10-29 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
WO2014204578A1 (fr) 2013-06-21 2014-12-24 The General Hospital Corporation Utilisation de nucléases foki à guidage arn (rfn) afin d'augmenter la spécificité pour l'édition de génome par guidage arn
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
EP3158066B1 (fr) 2014-06-23 2021-05-12 The General Hospital Corporation Identification non biaisée, pangénomique, de dsb évaluée par séquençage (guide-seq)
KR102455807B1 (ko) 2014-10-01 2022-10-18 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017044843A1 (fr) 2015-09-11 2017-03-16 The General Hospital Corporation Interrogation complète de dsb nucléasiques et séquençage (find-seq)
US9850484B2 (en) 2015-09-30 2017-12-26 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
CN110290813A (zh) 2016-10-14 2019-09-27 通用医疗公司 表观遗传学调控的位点特异性核酸酶
AU2018273968A1 (en) 2017-05-25 2019-11-28 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
EP3921417A4 (fr) 2019-02-04 2022-11-09 The General Hospital Corporation Variants d'éditeur de base d'adn adénine avec édition d'arn hors cible réduite
US12344850B2 (en) 2019-07-30 2025-07-01 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
EP3812472B1 (fr) 2019-10-21 2022-11-23 Albert-Ludwigs-Universität Freiburg Dosage in vitro vraiment non biaisé pour profiler une activité hors cible d'une ou de plusieurs nucléases programmables spécifiques à une cible dans des cellules (abnoba-seq)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANDRASEGARAN S.: "Chimeric Restriction Enzymes: What is Next?", BIOLOGICAL CHEMISTRY, vol. 380, 1999, pages 841 - 848, XP008019125 *
CHOCO Y. ET AL.: "In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence", NATURE, vol. 372, 15 December 1994 (1994-12-15), pages 642 - 645, XP003001072 *
HANES J. ET AL.: "Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems", FEBS., vol. 450, 1999, pages 105 - 110, XP002178365 *
WOLFE S. A. ET AL.: "Combining structure-based design with phage display to create new Cy2His2 zinc finger dimers", STRUCTURE, vol. 8, 21 June 2000 (2000-06-21), pages 739 - 750, XP008070579 *

Also Published As

Publication number Publication date
AU2003304086A8 (en) 2004-11-26
AU2003304086A1 (en) 2004-11-26
WO2004099366A2 (fr) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2004099366A3 (fr) Optimisation parallele sensible au contexte de domaines de liaison a l'adn en doigt de zinc
WO2004092219A3 (fr) Modification d'affinites de liaison pour fcrn ou de demi-vies de serum d'anticorps par mutagenese
EP1789447A4 (fr) Méthode d'interférence arn et utilisations
WO2005123780A3 (fr) Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
ATE480562T1 (de) Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
WO2004033631A8 (fr) Sequences d'acides nucleiques et polypeptidiques de lawsonia intracellularis et methodes d'utilisation
EP1864998A3 (fr) Molécules de liaison
WO2001049823A3 (fr) Dosage pour la detection de bacillus anthracis
WO2004074310A8 (fr) Diagnostics de mycobactéries
SI1697421T1 (sl) Bispecifična protitelesa
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
WO2008022152A3 (fr) Anticorps optimisés ciblant cd19
WO2005011376A3 (fr) Anticorps modifies presentant une affinite de liaison a l'antigene amelioree
WO2003074679A3 (fr) Optimisation d'anticorps
WO2008036688A3 (fr) Anticorps optimisés ciblant l'antigène hm1.24
WO2004046306A3 (fr) Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain
WO2003093472A3 (fr) Acides nucleiques liant le cgrp
WO2003087138A3 (fr) Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn
WO2001051669A3 (fr) Methode de dosage et de selection pour sites de liaison aux acides nucleiques
EP1801208A4 (fr) Anticorps anti-a33
DE60031965D1 (de) Hochsensitiver nachweis von biomolekülen mittels "phage display"
WO2006033742A3 (fr) Fragment d'anticorps genetiquement modifie qui se lie a un antigene de maniere irreversible
WO2004081029A3 (fr) Nouveau marqueur non invasif des maladies du foie
WO2004027421A3 (fr) Dosage adp
WO2009045075A3 (fr) Anticorps monoclonal spécifique des cellules souches embryonnaires humaines, hybridome sécrétant ce dernier et procédé permettant de détecter ou d'isoler une cellule souche embryonnaire non différenciée

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWE Wipo information: entry into national phase

Ref document number: 10532258

Country of ref document: US

Ref document number: 2007178454

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10532258

Country of ref document: US